ERBB2 and gastric cancer: The KEYNOTE-811 trial corroborated that incorporating pembrolizumab with trastuzumab and chemotherapy significantly improved the objective response rate of patients with HER2-positive GC, especially those with a PD-L1 combined positive score ≥ 1, underscoring the potential of this combination [18].